A number of other brokerages have also recently commented on NOVN. Deutsche Bank AG set a CHF 78 price target on shares of Novartis AG and gave the company a neutral rating in a research note on Wednesday, June 21st. S&P Global set a CHF 82 target price on shares of Novartis AG and gave the stock a neutral rating in a report on Tuesday, July 18th. Goldman Sachs Group, Inc. (The) set a CHF 80 target price on shares of Novartis AG and gave the stock a neutral rating in a report on Thursday, July 20th. Barclays PLC set a CHF 80 target price on shares of Novartis AG and gave the stock a neutral rating in a report on Friday, June 23rd. Finally, Jefferies Group LLC set a CHF 103 target price on shares of Novartis AG and gave the stock a buy rating in a report on Friday, June 23rd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and seven have assigned a buy rating to the stock. The company currently has an average rating of Hold and a consensus target price of CHF 85.17.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Markets Daily and is the property of of Markets Daily. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.themarketsdaily.com/2017/10/13/novartis-ag-novn-given-a-chf-90-price-target-at-hsbc-holdings-plc.html.
Novartis AG Company Profile
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.